Global market size
$203B
↑ 9.1% CAGR to 2030
Hottest segment
Gut health
↑ 7.3% yr  ·  +$4.7B by 2028
Ingredient of the month
Berberine
↑ 108K Amazon searches / week
Regulatory watch
NMN  ·  EU
Novel food auth. pending
Top five signals this month Ranked by consultant relevance
01
Regulatory FTC
A federal court dismisses Xlear's challenge to the FTC's substantiation standard

The U.S. District Court for the District of Utah dismissed Xlear, Inc. v. FTC (No. 2:25-cv-00484-DBB-CMR, decided July 27, 2026) for lack of subject-matter jurisdiction, finding the dispute unripe. The court noted the FTC had already dropped its underlying enforcement case against Xlear in 2025, leaving no final agency action to challenge, and it did not reach the merits of whether the substantiation requirement exceeds the FTC's statutory authority.

So what: The FTC's existing substantiation framework stands untouched. Clients should keep building RCT-level support for health claims rather than wait for a legal opening that this ruling does not provide.

Consumer search and social signals also inform velocity rating.

Velocity
02
Claim enforcement FTC
FTC escalates to a contempt motion against Amare Global over health claims

In June 2026 the FTC filed a motion seeking a contempt order against Amare Global and three individuals, alleging continued unsubstantiated depression, anxiety, and ADHD claims after an earlier settlement agreement.

So what: Escalation from standard enforcement to contempt shows the FTC treating repeat violations of existing orders as a priority. Clients operating under any consent order should treat compliance as a live, ongoing obligation, not a closed chapter.

Consumer search and social signals also inform velocity rating.

Velocity
03
Women's health Clinical evidence
A new RCT strengthens the case for creatine in perimenopausal and menopausal women

An 8-week trial of creatine hydrochloride and creatine ethyl ester reported measurable cognition and strength benefits in a perimenopausal and menopausal population, adding direct clinical data where the category previously leaned on general sports-nutrition research.

So what: Brands marketing creatine to midlife women can now cite population-specific RCT evidence instead of extrapolating from younger-athlete studies.

Consumer search and social signals also inform velocity rating.

Velocity
04
Nootropics Safety risk
Methylene blue's wellness following keeps outrunning its safety data

Widely syndicated reporting in late 2025 laid out the serotonin-toxicity and G6PD-deficiency risks behind a drug most retailers sell without a supplement-registry listing. Biohacker demand, amplified by unconfirmed celebrity speculation, continues to outpace any resolution of its regulatory status.

So what: This remains a liability-exposure watch item, not a formulation opportunity. Clients should avoid branding anything adjacent to it.

Consumer search and social signals also inform velocity rating.

Velocity
05
Gut health Clinical pipeline
Postbiotic research moves from pipeline to active human enrollment

Multiple new ClinicalTrials.gov listings, covering gut-health biomarkers, exercise-induced inflammation, and broader GI and immune symptoms, show postbiotics moving from preclinical signal into active human trial activity.

So what: The evidence base clients have been waiting for is now in motion. Track readouts over the next 12 to 18 months rather than continuing to treat postbiotics as speculative.

Consumer search and social signals also inform velocity rating.

Velocity
Ingredients to watch
Ashwagandha
Withania somnifera has moved past emerging status into a mainstay ingredient. The remaining opportunity is format innovation, not category education.
GLP-1 companion formulas
A formulation category, not a single ingredient: protein, fiber, magnesium, B12, and bioflavonoids for GLP-1 drug users. Speed to shelf matters more than a perfected formula in this compressed launch window.
Postbiotics
Heat-inactivated strains, cell fragments, and fermentates. The next shelf-stable claim vehicle, opening categories such as bars and beverages that live probiotics could never enter.
Methylene blue
Biohacker nootropic use is outrunning safety data. A watch item for liability exposure, not a formulation opportunity.
Regulatory radar
WatchFTC contempt motion against Amare Global. Repeat violations of existing orders are now an enforcement priority.
WatchMoringa leaf powder Salmonella outbreak spans at least four brands. FDA status ongoing as of its May 27, 2026 update.
MonitorNMN lawful, NDIN still required. No new filing, litigation, or enforcement this cycle.
MonitorFDA enforcement discretion on DSHEA disclaimer placement continues while rulemaking proceeds.
MonitorXlear v. FTC dismissed July 27, 2026 on ripeness. The FTC substantiation framework stands; the merits question is unresolved.